Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.

ABSTRACT:

Background

PD-1 blocking agents, such as nivolumab, have demonstrated clear anti-tumor effects and clinical benefits in a subset of patients with advanced malignancies. Nonetheless, more efforts are needed to identify reliable biomarkers for outcome, to correctly select patients who will benefit from anti-PD-1 treatment. The aim of this study was to investigate the role of peripheral CD8+T cells expressing CD73, involved in the generation of the immune suppressive molecule adenosine, in predicting outcome after nivolumab treatment in advanced melanoma patients.

Methods

PBMCs from 100 melanoma patients treated with nivolumab were collected at National Cancer Institute "G. Pascale" of Naples. Frequencies of CD8+ lymphocytes phenotypes were assessed by flow cytometry at baselin

SUBMITTER: Capone M 

PROVIDER: S-EPMC7065327 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature